<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">BELGE, GAZANFER</style></author><author><style face="normal" font="default" size="100%">GROBELNY, FRANCESCA</style></author><author><style face="normal" font="default" size="100%">MATTHIES, CORD</style></author><author><style face="normal" font="default" size="100%">RADTKE, ARLO</style></author><author><style face="normal" font="default" size="100%">DIECKMANN, KLAUS-PETER</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">163-168</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.11757</style></doi><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Clinical management of testicular germ cell tumours (GCT) is based upon the measurement of serum tumour markers. Recent studies have shown that the microRNA-371a-3p is a sensitive and specific serum biomarker for all subgroups of GCT, except teratoma. To close the diagnostic gap relating to teratoma, serum levels of microRNA-375-3p have recently been suggested to represent a specific serum marker of this histological subgroup. In the present study, we tested this hypothesis. Materials and Methods: miRNA expression was analysed in serum of 21 GCT patients with teratoma, twelve patients with other GCT, and twelve male controls using the qPCR method. Results: The serum miR-375-3p levels of teratoma patients were not different from other GCT patients or controls. The ROC analysis revealed an AUC of 0.524 for the discrimination between teratoma and other pathologies. Conclusion: The miR-375-3p does probably not qualify for a useful serum biomarker to distinguish teratoma from other GCTs and from controls.</style></abstract></record></records></xml>